Displaying drugs 13451 - 13475 of 14493 in total
Stamulumab
MYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases including muscular dystrophy and age-related sarcopenia.
Investigational
RTA 744
RTA 744 is a novel anthracycline derivative that crosses the blood-brain barrier and shows significant potential for the treatment of primary and metastatic brain cancers. Anthracyclines are one of the most broadly used and effective classes of cancer therapies; however, they are not used to treat brain cancers because current...
Investigational
Matched Description: … Anthracyclines are one of the most broadly used and effective classes of cancer therapies; however, they ... anthracycline derivative that crosses the blood-brain barrier and shows significant potential for the treatment of …
Garenoxacin
Garenoxacin, a quinolone antibiotic, is being investigated for the treatment of gram-positive and gram-negative bacterial infections.
Investigational
Matched Description: … Garenoxacin, a quinolone antibiotic, is being investigated for the treatment of gram-positive and gram-negative …
Matched Salts cas: … 223652-90-2 …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Matched Salts cas: … 223652-90-2 …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
ASI402
ASI402 is a monoclonal antibody that targets an aberrantly glycosylated antigen Mucin 1. It is being investigated in cancers.
Investigational
Matched Description: … It is being investigated in cancers. …
Sumanirole
Investigational
Matched Iupac: … (10R)-10-(methylamino)-1,3-diazatricyclo[6.3.1.0^{4,12}]dodeca-4,6,8(12)-trien-2-one …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Liatermin
Investigational
7-beta-Hydroxyepiandrosterone
Investigational
Vipadenant
Investigational
Matched Iupac: … 3-[(4-amino-3-methylphenyl)methyl]-7-(furan-2-yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine …
IMA901
IMA901 is a vaccine consists of tumor-associated peptides (TUMAPs).
Investigational
Matched Description: … IMA901 is a vaccine consists of tumor-associated peptides (TUMAPs). …
Asoprisnil
Asoprisnil (J867) is a selective progesterone receptor modulator. It can be used to treat progesterone sensitive myomata.
Investigational
Delcasertib
Investigational
SUVN-502
SUVN-502 is a novel, potent, safe, highly selective and orally active antagonist at a central nervous system serotonin receptor site 5-HT6 intended for treatment of cognitive disorders such as Alzheimer’s and Schizophrenia, an unmet medical need.
Investigational
Matched Iupac: … 1-(2-bromobenzenesulfonyl)-5-methoxy-3-[(4-methylpiperazin-1-yl)methyl]-1H-indole …
Matched Description: … active antagonist at a central nervous system serotonin receptor site 5-HT6 intended for treatment of …
Matched Salts cas: … 1791396-45-6 …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Matched Description: … active antagonist at a central nervous system serotonin receptor site 5-HT6 intended for treatment of …
Matched Salts cas: … 1791396-45-6 …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Pegpleranib
Investigational
EVT-101
Investigational
Matched Iupac: … 5-[3-(difluoromethyl)-4-fluorophenyl]-3-[(2-methyl-1H-imidazol-1-yl)methyl]pyridazine dihydrochloride …
Ibudilast
Ibudilast is an anti-inflammatory and neuroprotective oral agent which shows an excellent safety profile at 60 mg/day and provides significantly prolonged time-to-first relapse and attenuated brain volume shrinkage in patients with relapsing-remitting (RR) and/or secondary progressive (SP) multiple sclerosis (MS). Ibudilast is currently in development in the U.S. (codes: AV-411...
Investigational
Matched Iupac: … 2-methyl-1-[2-(propan-2-yl)pyrazolo[1,5-a]pyridin-3-yl]propan-1-one …
Matched Description: … Ibudilast is currently in development in the U.S. ... (codes: AV-411 or MN-166), but is approved for use as an antiinflammatory in Japan. ... day and provides significantly prolonged time-to-first relapse and attenuated brain volume shrinkage in …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Matched Description: … Ibudilast is currently in development in the U.S. ... (codes: AV-411 or MN-166), but is approved for use as an antiinflammatory in Japan. ... day and provides significantly prolonged time-to-first relapse and attenuated brain volume shrinkage in …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
EDP1815
EDP1815, was investigated in several clinical trials (NCT05066373, NCT05439941, NCT05682222, NCT03733353, NCT04603027, NCT04488575, NCT05121480, NCT04393246) to evaluate its safety and efficacy in conditions such as gastrointestinal behavior, atopic dermatitis, psoriasis, skin inflammation, and COVID-19.
Investigational
Matched Description: … EDP1815, was investigated in several clinical trials (NCT05066373, NCT05439941, NCT05682222, NCT03733353 ... , NCT04603027, NCT04488575, NCT05121480, NCT04393246) to evaluate its safety and efficacy in conditions …
HY10275
HY10275 is a novel compound specifically designed to modulate two key neurobiological mechanisms that interfere with the sleeping process. HY10275 is highly selective for histamine H1 and serotonin 5HT2a, two chemical receptors that are known to impact the ability to fall asleep and stay asleep. HY10275 was rationally designed to...
Investigational
Matched Description: … This dual-acting receptor activity and the lack of affinity for undesired off- target receptors are thought …
PEV3A
PEV3A is a prophylactic malaria vaccine that acts against various stages of the disease. It is a two-component vaccine that contains the virosome formulated peptide mimetics PEV301 and PEV302. The two synthetic peptide vaccine components mimic the native structure of important antigens of the malaria parasite. The elicited antibodies are...
Investigational
Matched Description: … The two synthetic peptide vaccine components mimic the native structure of important antigens of the ... PEV3A is a prophylactic malaria vaccine that acts against various stages of the disease. …
MB07811
MB07811 is the first of a novel class of product candidates discovered by Metabasis designed to lower serum cholesterol and triglycerides. MB07811, a small molecule that is administered orally, has been extensively studied preclinically and is currently undergoing clinical testing. MB07811 combines a novel thyroid hormone receptor agonist with the...
Investigational
Matched Description: … MB07811 is the first of a novel class of product candidates discovered by Metabasis designed to lower ... The combination of selectivity for the beta form of the receptor, liver targeting and other structural ... is designed to provide significant efficacy while avoiding side effects associated with activation of …
SPP1148
SPP1148, the most promising compound from a new series of renin inhibitors for the treatment of hypertension and related end-organ disease.
Investigational
Matched Description: … SPP1148, the most promising compound from a new series of renin inhibitors for the treatment of hypertension …
TAK-475
TAK-475 is a "squalene synthase inhibitor", a type of cholesterol-lowering drug that has not yet been brought to market.
Investigational
Matched Description: … TAK-475 is a "squalene synthase inhibitor", a type of cholesterol-lowering drug that has not yet been …
MIV-701
MIV-701 is a selective, potent inhibitor of the protease Cathepsin K. It is developed for the treatment of osteoporosis.
Investigational
Matched Description: … It is developed for the treatment of osteoporosis. ... MIV-701 is a selective, potent inhibitor of the protease Cathepsin K. …
LCP-AtorFen
LCP-AtorFen is a fixed-dose combination therapy for the treatment of high cholesterol levels combining atorvastatin (the active ingredient of Lipitor®) and the lowest dose of fenofibrate without food effect. LCP-AtorFen is designed to be a once daily tablet offering a powerful and safe treatment of high cholesterol levels, addressing three...
Investigational
Matched Description: … atorvastatin (the active ingredient of Lipitor®) and the lowest dose of fenofibrate without food effect ... LCP-AtorFen is a fixed-dose combination therapy for the treatment of high cholesterol levels combining ... LCP-AtorFen is designed to be a once daily tablet offering a powerful and safe treatment of high cholesterol …
ETC-1001
ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.
Investigational
MK-0354
MK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders. It targets G protein-coupled receptor, or GPCR, that have the potential to regulate plasma lipid profiles, including HDL, or the good cholesterol, similar to the therapeutic action of niacin.
Investigational
Matched Description: … MK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis ... regulate plasma lipid profiles, including HDL, or the good cholesterol, similar to the therapeutic action of …
Displaying drugs 13451 - 13475 of 14493 in total